Goldman Sachs’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-373,720
Closed -$22.3M 5654
2020
Q2
$22.3M Buy
373,720
+264,365
+242% +$16.3M 0.01% 1592
2020
Q1
$6.49M Buy
109,355
+48,341
+79% +$2.82M ﹤0.01% 2427
2019
Q4
$3.34M Buy
61,014
+31,429
+106% +$1.17M ﹤0.01% 3261
2019
Q3
$836K Buy
29,585
+21,453
+264% +$787K ﹤0.01% 4148
2019
Q2
$270K Buy
8,132
+105
+1% +$3.28K ﹤0.01% 4659
2019
Q1
$273K Sell
8,027
-4,226
-34% -$134K ﹤0.01% 4676
2018
Q4
$336K Sell
12,253
-65,643
-84% -$1.69M ﹤0.01% 4582
2018
Q3
$2.28M Buy
+77,896
New +$2.2M ﹤0.01% 3514

Other funds holding PRNB

Goldman Sachs's PRNB Position: Q3 2020 in Review

Goldman Sachs sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 373,720 shares — an estimated $22.3M sold.

Goldman Sachs first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $22.3M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Goldman Sachs reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Goldman Sachs sold 373,720 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $22.3M.
  • Goldman Sachs first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Goldman Sachs's Principia Biopharma Inc. Common Stock position peaked at $22.3M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.